CD4


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
06 05 2022
Historique:
received: 22 01 2022
accepted: 22 04 2022
revised: 21 04 2022
entrez: 6 5 2022
pubmed: 7 5 2022
medline: 11 5 2022
Statut: epublish

Résumé

As a widely studied adoptive treatment method, CIK (cytokine-induced killer cells) treatment has shown clinical benefits in many clinical trials on non-small cell lung cancer. As a heterogeneous cell population, however, CIK cells have a strong instability and individual differences in their efficacies, which are collaboratively regulated by the tumor microenvironment and CIK subpopulations. Among them, CD4

Identifiants

pubmed: 35523765
doi: 10.1038/s41419-022-04882-x
pii: 10.1038/s41419-022-04882-x
pmc: PMC9076680
doi:

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

441

Informations de copyright

© 2022. The Author(s).

Références

Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Immunotherapy. 2011 Oct;3(10):1223-33
pubmed: 21995573
Int Immunopharmacol. 2015 Apr;25(2):450-6
pubmed: 25698555
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Immunity. 2019 Dec 17;51(6):1028-1042.e4
pubmed: 31810883
Biomed Pharmacother. 2019 Jan;109:1728-1739
pubmed: 30551427
J Immunother. 2013 Oct;36(8):451-8
pubmed: 23994890
Cell Metab. 2020 Jan 7;31(1):148-161.e5
pubmed: 31761565
Cytokine Growth Factor Rev. 2017 Aug;36:99-105
pubmed: 28629761
Immunity. 2004 Apr;20(4):477-94
pubmed: 15084276
J Clin Invest. 2020 Jul 1;130(7):3560-3575
pubmed: 32229721
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727783
Front Immunol. 2021 Oct 05;12:761920
pubmed: 34675939
Int J Hematol. 2014 Aug;100(2):165-70
pubmed: 24929848
Signal Transduct Target Ther. 2020 Oct 19;5(1):244
pubmed: 33077722
Cancer Res. 2012 Jul 15;72(14):3570-81
pubmed: 22581824
Nat Immunol. 2019 Jul;20(7):879-889
pubmed: 31182807
Cancer Cell. 2018 Jun 11;33(6):1048-1060.e7
pubmed: 29894691
J Exp Med. 2015 Mar 9;212(3):333-49
pubmed: 25732306
J Exp Med. 2013 Jul 1;210(7):1463-79
pubmed: 23776078
Oncol Lett. 2021 Aug;22(2):613
pubmed: 34257721
Nat Rev Immunol. 2011 Feb;11(2):109-17
pubmed: 21233853
Gastroenterology. 2015 Jun;148(7):1383-91.e6
pubmed: 25747273
Cytotherapy. 2014 Jun;16(6):835-44
pubmed: 24582456
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8
pubmed: 20679213
Hepatology. 2020 Oct;72(4):1310-1326
pubmed: 33090557
Front Immunol. 2016 Jun 20;7:241
pubmed: 27379101
Nat Rev Immunol. 2016 Feb;16(2):102-11
pubmed: 26781939
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
J Clin Med. 2019 Jun 12;8(6):
pubmed: 31212870
J Clin Immunol. 2007 May;27(3):317-26
pubmed: 17468835
Clin Cancer Res. 2012 Mar 15;18(6):1751-9
pubmed: 22275504
Nat Commun. 2017 Jun 06;8:15776
pubmed: 28585539
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
J Cancer Res Clin Oncol. 2017 May;143(5):861-871
pubmed: 28108815

Auteurs

Shaochuan Liu (S)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Yuan Meng (Y)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Liang Liu (L)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Yingge Lv (Y)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Wenwen Yu (W)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Ting Liu (T)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Limei Wang (L)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Di Mu (D)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Qiuru Zhou (Q)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Min Liu (M)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Yulin Ren (Y)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Dong Zhang (D)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Baihui Li (B)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Qian Sun (Q)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. sunqian923@126.com.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. sunqian923@126.com.
Tianjin's Clinical Research Center for Cancer, Tianjin, China. sunqian923@126.com.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. sunqian923@126.com.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. sunqian923@126.com.

Xiubao Ren (X)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. renxiubao@tjmuch.com.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. renxiubao@tjmuch.com.
Tianjin's Clinical Research Center for Cancer, Tianjin, China. renxiubao@tjmuch.com.
Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. renxiubao@tjmuch.com.
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. renxiubao@tjmuch.com.
Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. renxiubao@tjmuch.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH